Clinical Trial

Methamphetamine Cue-reactivity

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this observational cohort study, the researchers propose to first identify a psychophysiological marker of methamphetamine cue-reactivity and its incubation with abstinence from methamphetamine use (MUD) and examine group-differences between men who have sex with men (MSM) and non-MSM MUD. The primary objective is to identify psychophysiological markers of methamphetamine (MA) cue-reactivity and its abstinence incubation. The secondary objective is to examine group-differences in methamphetamine use disorder (MUD) individuals between homosexual men (MSM) and heterosexual men (non-MSM). The primary endpoint is to assess incubation of cue-reactivity longitudinally with its reduction in cognitive reappraisal, and the secondary endpoint is to examine the impact of cognitive reappraisal on clinical outcomes of methamphetamine use disorder (MUD) in homosexual men (MSM). 2-year long study. Screening and enrollment will be done at different locations of the Addiction Institute of Mount Sinai. The EEG session will be done at Icahn School of Medicine at Mount Sinai. Participation in the research study will be for a single EEG session.
Trial Details
NCT Number NCT07086014
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Methamphetamine Use Disorder
Enrollment 88 participants
Start Date 2024-08-19
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-25